Raymond James Financial
MAZE

Raymond James Financial’s Maze Therapeutics MAZE Stock Holding History

Raymond James Financial’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.07M Buy
69,375
+1,657
+2% +$73.1K ﹤0.01% 3344
2025
Q4 		$2.81M Buy
+67,718
New +$2.33M ﹤0.01% 2998

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Raymond James Financial's MAZE Position: Q1 2026 in Review

Raymond James Financial increased its Maze Therapeutics (MAZE) stake by 2.4% in Q1 2026, buying an estimated $73.1K and bringing the position to 69,375 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3344.

Raymond James Financial first reported a position in MAZE in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.81M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Raymond James Financial held 69,375 shares of Maze Therapeutics worth $2.07M as of Q1 2026.
  • Raymond James Financial bought 1,657 Maze Therapeutics shares in Q1 2026, an estimated $73.1K.
  • Maze Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3344 holding.
  • Raymond James Financial first reported a position in Maze Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Raymond James Financial's Maze Therapeutics position peaked at $2.81M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.